AFP Test · Blood

If you have chronic hepatitis B, hepatitis C, or cirrhosis of any cause, your single greatest cancer risk is hepatocellular carcinoma, the most common form of primary liver cancer. It develops silently, often producing no symptoms until the tumor is large enough to cause pain, weight loss, or jaundice (yellowing of the skin and eyes). By then, curative options shrink dramatically. AFP (alpha-fetoprotein) is the oldest and most widely used blood test for spotting liver cancer early, and it remains a core part of surveillance programs worldwide.

A normal AFP does not guarantee your liver is cancer-free, and a mildly elevated AFP does not mean you have cancer. About 30 to 40% of liver cancers never raise AFP at all, and chronic liver inflammation can push AFP up without any tumor present. That tension is exactly why understanding this test, its strengths, its blind spots, and how to use it alongside imaging, matters so much.

What AFP Is and Why It Reappears

AFP is a large protein closely related to albumin, the most abundant protein in adult blood. During fetal development, AFP is the dominant protein in your bloodstream, produced first by the yolk sac and then by the fetal liver. It acts as a carrier molecule, transporting fats, metals, and other substances the developing body needs. After birth, production shuts down rapidly, and AFP is replaced by albumin. In healthy adults, AFP stays extremely low, typically under 10 ng/mL.

Scientists classify AFP as an "oncofetal" protein, meaning it belongs to fetal development but can switch back on in certain cancers. When liver cells become cancerous, changes in their DNA can unlock the AFP gene again. The more aggressive the tumor, the more likely it is to produce large amounts of AFP. This reactivation is what makes AFP useful as a cancer signal, though not every liver tumor flips this switch.

Liver Cancer Detection

AFP is primarily used to watch for liver cancer in people who already have chronic liver disease. A meta-analysis pooling data from multiple studies found that how well AFP performs depends heavily on where you set the bar. At a cutoff of 20 to 100 ng/mL, AFP catches about 61% of liver cancers while correctly clearing about 86% of people without cancer. Raise the cutoff to 400 ng/mL and it becomes extremely specific, correctly identifying 99% of non-cancer cases, but it catches only about 32% of actual cancers.

That tradeoff between catching more cancers and generating more false alarms is why AFP works best as a team player rather than a solo act. A large meta-analysis found that adding AFP to abdominal ultrasound increased the detection rate for early-stage liver cancer from roughly 45% with ultrasound alone to about 63% with both. In some datasets, the combination detected very early cancers at rates exceeding 88%. The takeaway: ultrasound without AFP misses tumors, and AFP without ultrasound misses even more.

For the best accuracy, a cutoff around 10 to 11 ng/mL appears to be the sweet spot for early detection, catching about 65 to 66% of early and very early liver cancers. That is lower than the traditional 20 ng/mL threshold many labs flag, and it is the reason some hepatologists now pay attention to even modest rises.

AFP and Prognosis

AFP is not just a detection tool. In people who do develop liver cancer, higher AFP levels consistently signal worse outcomes. A study of 376 patients who had liver cancer surgically removed found that those with AFP above 400 ng/mL were about 1.8 times as likely to die during follow-up compared to those with lower levels. They were also roughly 1.7 times as likely to have their cancer come back.

In a massive analysis of over 45,000 liver transplant recipients in the United States, AFP level at the time of transplant independently predicted survival afterward. Compared to patients without liver cancer, those with AFP between 66 and 320 ng/mL had about 65% higher mortality, and those above 320 ng/mL had roughly 2.4 times the risk of death, even after accounting for tumor size and number.

Perhaps most useful is what happens to AFP during treatment. A meta-analysis of 29 studies covering nearly 4,700 liver cancer patients found that those whose AFP fell after treatment (surgery, transplant, or systemic therapy) had dramatically better outcomes: roughly 59% lower risk of death and 54% lower risk of disease progression compared to non-responders. If your AFP drops after treatment, that is a strong sign the therapy is working.

The AFP-Negative Blind Spot

One of the most important things to understand about AFP is that a normal result does not rule out liver cancer. In a study of over 1,600 liver cancer patients, roughly 46% had AFP below 20 ng/mL. These "AFP-negative" tumors tend to be smaller, better differentiated (meaning the cancer cells still somewhat resemble normal liver cells), and less likely to have spread into nearby blood vessels. Patients with AFP-negative cancer generally have better survival after surgery, which is encouraging, but it also means AFP alone would have missed nearly half of all cases.

This is why companion markers exist. PIVKA-II (also called DCP), a protein produced by liver cancers that do not secrete AFP, can detect tumors that AFP misses entirely. A study of hepatitis C-related liver cancer found that PIVKA-II had 78% sensitivity compared to AFP's 56% at standard cutoffs. AFP-L3, a cancer-specific form of AFP, adds further precision but is only measurable when total AFP is above about 10 to 20 ng/mL. Using all three together, or combining them into composite scores, consistently outperforms any single marker.

Beyond Liver Cancer

While liver cancer is the primary reason to order AFP, other conditions can elevate it. Chronic hepatitis and cirrhosis, especially from hepatitis B or C, often produce mild to moderate AFP elevations (roughly 10 to 200 ng/mL) due to ongoing liver cell turnover and inflammation, with no tumor present. Effective antiviral therapy can bring these levels back down. Germ cell tumors, particularly certain testicular and ovarian cancers, are another well-known cause of elevated AFP. And a handful of rare inherited neurological conditions, including ataxia-telangiectasia, cause chronically elevated AFP through a mechanism unrelated to liver damage.

A small but interesting group of apparently healthy adults carry mildly elevated AFP (7 to 200 ng/mL) for reasons that are unclear. In at least one cohort followed for a median of 13 months, none developed cancer, their levels stayed stable, and they actually had less liver fat and better muscle quality than comparison groups. This suggests that mild, stable AFP elevation in the absence of liver disease is often benign, though it warrants monitoring.

Reference Ranges

These ranges come from large multicenter studies and meta-analyses of adult patients, measured by standard immunoassay in serum. They are used across clinical guidelines but your lab may report slightly different cutpoints depending on the assay platform.

Compare your results within the same lab over time for the most meaningful trend. A single reading in any range is less informative than the direction your number is moving.

When Results Can Be Misleading

The biggest confounder for AFP is active liver inflammation. If your liver enzymes (ALT in particular) are elevated because of a hepatitis flare, autoimmune liver disease, or heavy alcohol use, your AFP can rise independently of any tumor. This is the most common source of false-positive AFP results and a frequent cause of unnecessary alarm.

• Active hepatitis flare: A spike in liver inflammation from viral hepatitis or autoimmune disease can push AFP into the 20 to 200 ng/mL range without any tumor present. Wait until inflammation settles and retest before drawing conclusions.
• Viral etiology: Chronic hepatitis B and C tend to produce higher background AFP levels than non-viral liver disease at the same stage of fibrosis, which lowers specificity in these populations.
• Pregnancy: AFP is physiologically elevated during pregnancy because the fetus produces it. This test should not be interpreted as a liver cancer screen in pregnant individuals.
• Recent liver procedures: Biopsy, ablation (a procedure that destroys tumor tissue with heat or cold), or chemoembolization (a procedure that delivers chemotherapy directly to the tumor and blocks its blood supply) can cause transient AFP changes due to cell injury and regeneration. Allow at least 4 to 8 weeks after a procedure before interpreting AFP as a disease indicator.

No well-documented evidence links common medications (statins, metformin, PPIs, corticosteroids) to clinically meaningful AFP changes, so routine medications are unlikely to produce misleading results.

Tracking Your Trend

A single AFP result is a snapshot. A series of results over months to years is a story. Longitudinal research tracking AFP in chronic liver disease patients found that gradual AFP rises, even within the "normal" range, can precede a liver cancer diagnosis by one to two years. People whose AFP climbed steadily had significantly higher risk of developing cancer than those whose levels stayed flat, regardless of the absolute number.

For anyone with cirrhosis or chronic hepatitis B, the standard surveillance interval is AFP plus abdominal ultrasound every six months. If you are making changes to treat underlying liver disease (antiviral therapy, alcohol cessation, weight loss for fatty liver), retesting AFP every three to six months lets you see whether your interventions are reducing liver stress. After any treatment for liver cancer, AFP should be checked at 4 to 8 weeks post-treatment, then every three months for at least the first two years.

A stable, low AFP over several years in someone with chronic liver disease is genuinely reassuring. A rising AFP, even from 3 to 8 ng/mL, should trigger closer imaging evaluation.

What to Do If Your AFP Is Elevated

An AFP above 20 ng/mL in someone with known liver disease should prompt cross-sectional imaging, typically a contrast-enhanced CT or MRI of the liver, not just ultrasound. If imaging is negative, retest AFP in three months and look at the trend. A rising AFP with negative imaging may warrant referral to a hepatologist (a liver specialist) for more advanced workup, including AFP-L3 and PIVKA-II testing or consideration of a composite score like GALAD (a scoring system that combines sex, age, AFP-L3, AFP, and PIVKA-II into a single risk estimate).

An AFP above 400 ng/mL combined with a liver mass on imaging is essentially diagnostic for liver cancer in someone with cirrhosis and often does not require biopsy for confirmation. At this level, the priority shifts to staging and treatment planning.

If your AFP is mildly elevated (10 to 20 ng/mL) and you have no known liver disease, the first step is to check liver enzymes, hepatitis B and C serologies (blood tests that detect current or past viral infection), and get a liver ultrasound. Most isolated mild elevations in healthy adults turn out to be benign, but they deserve a thorough initial evaluation and follow-up testing in three to six months to confirm stability.